

D1 cont'd  
characteristic of T-cell receptor beta-like protein].

Docket No.: PF-0346-1 DIV

D2  
13. (Once Amended) A [pharmaceutical] composition comprising a [substantially] purified T-cell receptor beta-like protein having the amino acid sequence of SEQ ID NO:1 in conjunction with a [suitable] pharmaceutical carrier.

**RECEIVED**

[Please add new claims 24-26 as follows.]

FEB - 1 2001

TECH CENTER 1600/2900

D3  
14. (New) A method for using a protein to screen a plurality of molecules or compounds to identify at least one ligand, the method comprising:

- a) combining the protein of claim 1 with the molecules or compounds under conditions to allow specific binding; and
- b) detecting specific binding, thereby identifying a ligand which specifically binds the protein.

15. (New) The method of claim 24 wherein the molecules or compounds are selected from DNA molecules, RNA molecules, peptide nucleic acids, peptides, proteins, mimetics, agonists, antagonists, antibodies, immunoglobulins, inhibitors, and drugs.

16. (New) A method of using a protein to prepare and purify antibodies comprising:

- a) immunizing an animal with the protein of claim 1 under conditions to elicit an antibody response;
- b) isolating animal antibodies;
- c) attaching the protein to a substrate;
- d) contacting the substrate with isolated antibodies under conditions to allow specific binding to the protein;
- e) dissociating the antibodies from the protein, thereby obtaining purified antibodies.

### REMARKS

Claims 1, 2, and 13-23 were originally filed and were subject to a Restriction Requirement. Applicants affirm election, with traverse, of original claims 1, 2 and 13, corresponding to the invention of Group I. Applicants reserve the right to prosecute the non-elected claims in subsequent divisional applications.